Purpose-built, high-precision MRD testing

Uncover residual disease with exquisite MRD detection sensitivity.

Exquisite sensitivity

Haystack MRD™

Minimal residual disease (MRD) testing demands the high sensitivity ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after definitive surgery.

Residual disease detection

Go beyond traditional methods for adjuvant chemotherapy guidance.

Treatment response assessment

Track ctDNA levels during adjuvant chemotherapy to monitor treatment response.

Disease recurrence surveillance

Detect disease relapse earlier than traditional methods.

Transformative precision

Dive deeper

Haystack Oncology was founded to dramatically improve patient outcomes by helping doctors optimize treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing ultrasensitive MRD testing for informed clinical management and therapeutic development.

The difference

Why Haystack MRD

Confident MRD results

Ultrasensitive ctDNA testing delivers the insights you need to make confident treatment decisions.

Transformative technology

Packed with the power of Quest

Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless for easier, more streamlined patient care. Visit questdiagnostics.com to learn more.

Haystack MRD

In the news

Find out what’s happening at Haystack Oncology and stay up-to-date with industry news.

Haystack MRD™ by Quest Diagnostics^® at SSO 2025

March 18, 2025

We invite you to connect with us at SSO 2025 to learn how Haystack MRD can help guide treatment decisions with confidence. From the perioperative setting to recurrence surveillance, Haystack MRD tracks ctDNA across the treatment management journey—empowering oncologists to make informed, timely treatment decisions.

Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care

January 21, 2025

Haystack MRD™ by Quest Diagnostics at ASCO GI 2025

January 15, 2025

We are excited to announce our participation in the 2025 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI) taking place January 23-25 in San Francisco, CA. Join us at the Quest Diagnostics table #91 to discover how our ultrasensitive minimal residual disease (MRD) testing is empowering oncologists with the insights needed to make confident treatment decisions for patients with GI cancers.